NCT03288636View on ClinicalTrials.gov

Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 8, 2017

Primary Completion Date

September 14, 2017

Study Completion Date

October 28, 2017

Conditions
HCV
Interventions
DRUG

Danoprevir

Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23

DRUG

Ritonavir

Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23

DRUG

Ravidasvir

Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23

DRUG

Placebo

Placebo

Trial Locations (1)

310003

The first hospital of Zhejiang province, Hangzhou

Sponsors
All Listed Sponsors
lead

Ascletis Pharmaceuticals Co., Ltd.

INDUSTRY

NCT03288636 - Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China | Biotech Hunter | Biotech Hunter